Literature DB >> 27560197

Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.

Ting-Wei Yu1,2, Ho-Yen Chueh1,2, Ching-Chou Tsai1,3, Cheng-Tao Lin1,2, Jiantai Timothy Qiu1,2,4.   

Abstract

Granulocyte macrophage-colony stimulating factor (GM-CSF) is a potent immunomodulatory cytokine that is known to facilitate vaccine efficacy by promoting the development and prolongation of both humoral and cellular immunity. In the past years we have generated a novel codon-optimized GM-CSF gene as an adjuvant. The codon-optimized GM-CSF gene significantly increased protein expression levels in all cells tested and helped in generating a strong immune responses against HIV-1 Gag and HPV-associated cancer. Here, we review the literature dealing with the adjuvant activity of GM-CSF both in animal models and clinical trials. We anticipate that the codon-optimized GM-CSF gene offers a practical molecular strategy for potentiating immune responses to tumor cell-based vaccinations as well as other immunotherapeutic strategies.

Entities:  

Keywords:  GM-CSF; cancer vaccine; cytotoxic T cells; immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 27560197      PMCID: PMC5215529          DOI: 10.1080/21645515.2016.1221551

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  80 in total

1.  Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia.

Authors:  Michael R Jeng; Paula E Naidu; Martha D Rieman; Carlos Rodriguez-Galindo; Kerri A Nottage; Donyell T Thornton; Chin-Shang Li; Winfred C Wiang
Journal:  Pediatr Blood Cancer       Date:  2005-08       Impact factor: 3.167

2.  Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.

Authors:  A E Chang; Q Li; D K Bishop; D P Normolle; B D Redman; B J Nickoloff
Journal:  Hum Gene Ther       Date:  2000-04-10       Impact factor: 5.695

3.  Parallels between cancer and infectious disease.

Authors:  Richard S Hotchkiss; Lyle L Moldawer
Journal:  N Engl J Med       Date:  2014-07-24       Impact factor: 91.245

4.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

5.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

6.  A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer.

Authors:  Weihua Yin; Qiushan He; Zhiming Hu; Zhong Chen; Mao Qifeng; Song Zhichun; Qu Zhihui; Nie Xiaoxia; Jinlong Li; Jimin Gao
Journal:  Vaccine       Date:  2010-07-12       Impact factor: 3.641

7.  Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.

Authors:  Jonathan W Simons; Michael A Carducci; Bahar Mikhak; Michael Lim; Barbara Biedrzycki; Flavia Borellini; Shirley M Clift; Kristen M Hege; Dale G Ando; Steven Piantadosi; Richard Mulligan; William G Nelson
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

Review 8.  Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care.

Authors:  Lori F Gentile; Alex G Cuenca; Philip A Efron; Darwin Ang; Azra Bihorac; Bruce A McKinley; Lyle L Moldawer; Frederick A Moore
Journal:  J Trauma Acute Care Surg       Date:  2012-06       Impact factor: 3.313

9.  Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors:  Alfons J M van den Eertwegh; Jurjen Versluis; H Pieter van den Berg; Saskia J A M Santegoets; R Jeroen A van Moorselaar; Tim M van der Sluis; Helen E Gall; Thomas C Harding; Karin Jooss; Israel Lowy; Herbert M Pinedo; Rik J Scheper; Anita G M Stam; B Mary E von Blomberg; Tanja D de Gruijl; Kristen Hege; Natalie Sacks; Winald R Gerritsen
Journal:  Lancet Oncol       Date:  2012-02-10       Impact factor: 41.316

10.  Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.

Authors:  Evan J Lipson; William H Sharfman; Shuming Chen; Tracee L McMiller; Theresa S Pritchard; January T Salas; Susan Sartorius-Mergenthaler; Irwin Freed; Sowmya Ravi; Hao Wang; Brandon Luber; Janice Davis Sproul; Janis M Taube; Drew M Pardoll; Suzanne L Topalian
Journal:  J Transl Med       Date:  2015-07-05       Impact factor: 5.531

View more
  9 in total

Review 1.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 2.  Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.

Authors:  Margaret E Gatti-Mays; Jason M Redman; Julie M Collins; Marijo Bilusic
Journal:  Hum Vaccin Immunother       Date:  2017-08-31       Impact factor: 3.452

Review 3.  Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?

Authors:  Marouan Benna; Jean-Baptiste Guy; Claire Bosacki; Omar Jmour; Majed Ben Mrad; Oleksandr Ogorodniitchouk; Saïd Soltani; Meiling Lan; Elisabeth Daguenet; Benoîte Mery; Sandrine Sotton; Nicolas Magné; Alexis Vallard
Journal:  Br J Radiol       Date:  2020-02-04       Impact factor: 3.039

4.  Enrichment of Ly6Chi monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model.

Authors:  Weidong Zhao; Xian Zhou; Gan Zhao; Qing Lin; Xianzheng Wang; Xueping Yu; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-07-12       Impact factor: 3.452

5.  Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.

Authors:  Elizabeth Q Littauer; Lisa K Mills; Nicole Brock; E Stein Esser; Andrey Romanyuk; Joanna A Pulit-Penaloza; Elena V Vassilieva; Jacob T Beaver; Olivia Antao; Florian Krammer; Richard W Compans; Mark R Prausnitz; Ioanna Skountzou
Journal:  J Control Release       Date:  2018-02-26       Impact factor: 9.776

Review 6.  Activities of stromal and immune cells in HPV-related cancers.

Authors:  Marconi Rego Barros; Cristiane Moutinho Lagos de Melo; Maria Luiza Carneiro Moura Gonçalves Rego Barros; Rita de Cássia Pereira de Lima; Antonio Carlos de Freitas; Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2018-07-05

7.  Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer.

Authors:  Kuan-Wei Huang; Fu-Fei Hsu; Jiantai Timothy Qiu; Guann-Jen Chern; Yi-An Lee; Chih-Chun Chang; Yu-Ting Huang; Yun-Chieh Sung; Cheng-Chin Chiang; Rui-Lin Huang; Chu-Chi Lin; Trinh Kieu Dinh; Hsi-Chien Huang; Yu-Chuan Shih; Donia Alson; Chun-Yen Lin; Yung-Chang Lin; Po-Chiao Chang; Shu-Yi Lin; Yunching Chen
Journal:  Sci Adv       Date:  2020-01-15       Impact factor: 14.136

8.  Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant.

Authors:  Weidong Zhao; Gan Zhao; Shuren Zhang; Xianzheng Wang; Xueping Yu; Bin Wang
Journal:  Oncotarget       Date:  2018-07-13

9.  FLT3L and granulocyte macrophage colony-stimulating factor enhance the anti-tumor and immune effects of an HPV16 E6/E7 vaccine.

Authors:  Zhenzhen Ding; Hua Zhu; Laiming Mo; Xiangyun Li; Rui Xu; Tian Li; Liang Zhao; Yi Ren; Yunsheng Xu; Rongying Ou
Journal:  Aging (Albany NY)       Date:  2019-12-24       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.